Rebamipide during chronic gastritis: <i>H. pylori</i> eradication therapy and restoration of gastric mucosa barrier function

Abstract

Аim: to present evidence justifying prescription of rebamipide during chronic gastritis.Key points. Experimental and clinical studies have demonstrated that rebamipide increases concentration of prostaglandins (prostaglandin E2 and prostacyclin) and production of mucin, manages inflammation and oxidative stress, controls apoptosis and autophagy. Pleiotropic effects of rebamipide are aimed at restoration of epithelium barrier function and can be implemented during chronic gastritis for various indications. When added to the H. pylori eradication therapy, rebamipide increases its effectiveness and tolerability. During atrophic gastritis, long-term treatment with rebamipide has resulted in reduction of degree of atrophy and intestinal metaplasia. Effectiveness of rebamipide during erosive gastritis, for treatment and prevention of stomach and duodenum disorders associated with nonste- roidal anti-inflammatory drugs is proven. Rebamipide manages symptoms of dyspepsia during chronic gastritis and during functional dyspepsia.Conclusion. Prescription of rebamipide during chronic gastritis for various indications is proved from the perspective of evidence-based medicine during H. pylori eradication therapy and for restoration of mucosa barrier function.

Keywords

• chronic gastritis
• <i>helicobacter pylori</i>
• rebamipide
• <i>h. pylori</i> eradication therapy
• erosive gastritis
• dyspepsia